Landos Biopharma (LABP)
(Delayed Data from NSDQ)
$22.80 USD
+0.50 (2.23%)
Updated May 22, 2024 03:58 PM ET
After-Market: $22.75 -0.05 (-0.21%) 5:52 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LABP 22.80 +0.50(2.23%)
Will LABP be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for LABP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LABP
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio
LABP: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma
5 Biotech Stocks Set to Outpace Q1 Earnings Estimates
Why Encompass Health (EHC) is Down 2.4% Since Q1 Earnings Beat
Other News for LABP
Landos Biopharma’s Latest Deal Faces Tough Regulatory Gauntlet: HSR Act and FTC Scrutiny May Impose Delays and Costs
LABP Stock Earnings: Landos Biopharma Misses EPS for Q1 2024
Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook
Maintaining Hold Rating on Landos Biopharma Amid Acquisition by AbbVie and Limited Upside Potential
Landos Biopharma just downgraded at H.C. Wainwright, here's why